3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
8
Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Basal Cell
2
Urologic Neoplasms
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Neoplasms
1
Urinary Bladder Diseases
1
Squamous Cell Carcinoma of Head and Neck
1
Neoplasms by Site
1
Nasopharyngeal Carcinoma
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Melanoma, Cutaneous Malignant
1
Male Urogenital Diseases
1
Locally Advanced Melanoma
1
Female Urogenital Diseases and Pregnancy Complications
1
Female Urogenital Diseases
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Interventions
relatlimab
1
pembrolizumab
1
lifileucel
1
Temozolomide
1
Paclitaxel
1
Opdualag
1
Nivolumab
1
Ipilimumab
1
Eye Movement Desensitization Reprocessing
1
Dacarbazine
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Melanoma, Cutaneous Malignant
×
relatlimab
×
Clear all
NCT06743126
2026-05-29
SUPRAME
Immatics US, Inc.
Phase 3
Recruiting
360 enrolled